<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Saudi J Anaesth</journal-id><journal-id journal-id-type="publisher-id">SJA</journal-id><journal-title-group><journal-title>Saudi Journal of Anaesthesia</journal-title></journal-title-group><issn pub-type="ppub">1658-354X</issn><issn pub-type="epub">0975-3125</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21189848</article-id><article-id pub-id-type="pmc">2980657</article-id><article-id pub-id-type="publisher-id">SJA-4-137</article-id><article-id pub-id-type="doi">10.4103/1658-354X.71409</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Study of the effect of oral gabapentin used as preemptive analgesia to attenuate post-operative pain in patients undergoing abdominal surgery under general anesthesia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Parikh</surname><given-names>Harshel G.</given-names></name><xref ref-type="aff" rid="AF0001"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Dash</surname><given-names>Sananta Kumar</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib><contrib contrib-type="author"><name><surname>Upasani</surname><given-names>Chitra B.</given-names></name><xref ref-type="aff" rid="AF0001"/></contrib></contrib-group><aff id="AF0001"><italic>Department of Anesthesia &#x00026; Critical Care, Grant Medical College &#x00026; Sir J.J. Group of Hospitals, Mumbai-08, India</italic></aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Harshel G. Parikh, 27/5, Prafull Society, Gokhale Road, Dahanukarwadi, Kandiwali (West), Mumbai - 400 067, India E-mail: <email xlink:href="dr.harshel82@gmail.com">dr.harshel82@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Dec</season><year>2010</year></pub-date><volume>4</volume><issue>3</issue><fpage>137</fpage><lpage>141</lpage><permissions><copyright-statement>&#x000a9; Saudi Journal of Anaesthesia</copyright-statement><copyright-year>2010</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Aims:</title><p>To study the effect of oral gabapentin used as preemptive analgesia to attenuate post operative pain in patients undergoing abdominal surgery under general anesthesia.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>In a randomized double blind study, 60 patients were divided into two groups. Group A received 600mg gabapentin and group B oral received placebo 1 h prior to surgery. Anesthesia was induced with Propofol 2 mg/kg and Vecuronium 0.1mg/kg and maintained with 60% N<sub>2</sub>O in O<sub>2</sub> and Vecuronium 0.02 mg/kg. All cases were given Fentanyl 2<italic>&#x000b5;</italic>g/kg as pre medication and a repeat dose 1<italic>&#x000b5;</italic>g/kg at the end of the first hour. Assessment of post-operative pain was made with the visual analog score (VAS) at extubation (0 h), 2, 4, 6, 12, and 24 h post-operatively. Post-operative analgesia was provided with intravenous Tramadol. The first dose was given in the Post Anesthesia Care Unit as 2mg/kg, and repeated at 8 and 16 h. Rescue analgesia was given with Diclofenac 1.5mg/kg, slow intravenous. The number of doses of rescue analgesia in both the groups was noted.</p></sec><sec id="st3"><title>Results:</title><p>The VAS scores at 0, 2, 4, 6, 12, and 24 h were 1.9 <italic>vs</italic>. 2.4 (<italic>P</italic>=0.002), 2.3 <italic>vs</italic>. 3.0 (<italic>P</italic>=0.000), 3.2 <italic>vs</italic>. 3.7 (<italic>P</italic>=0.006), 2.9 <italic>vs</italic>. 4.4 (<italic>P</italic>=0.000), 3.6 <italic>vs</italic>. 4.6 (<italic>P</italic>=0.000), and 3.7 <italic>vs</italic>.4.6 (<italic>P</italic>=0.000), respectively. Numbers of patients requiring rescue analgesia with Diclofenac were 3 <italic>vs</italic>. 14 (<italic>P</italic>=0.004).</p></sec><sec id="st4"><title>Conclusion:</title><p>A single oral dose of gabapentin given pre-operatively enhanced the analgesic effect of Tramadol as it also reduced the requirement of rescue analgesia with Diclofenac.</p></sec></abstract><kwd-group><kwd><italic>Abdominal surgery</italic></kwd><kwd><italic>gabapentin</italic></kwd><kwd><italic>pre-emptive analgesia</italic></kwd><kwd><italic>post-operative pain</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Post-operative pain is not purely nociceptive in nature and may consist of inflammatory, neurogenic, and visceral components. Therefore, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are becoming increasingly popular.[<xref ref-type="bibr" rid="CIT1">1</xref>] Post-operative pain affects recovery from surgery and anesthesia. The use of opioids by patient-controlled analgesia is popular, but limited by side-effects and by the fact that certain types of pain respond poorly to opioids.[<xref ref-type="bibr" rid="CIT2">2</xref>] Because of the multiplicity of the mechanisms involved in post-operative pain, a multimodal analgesia regimen with a combination of opioid and non-opioid analgesic drugs is often used to enhance analgesic efficacy and reduce opioid requirements and side-effects.[<xref ref-type="bibr" rid="CIT3">3</xref>]</p><p>Gabapentin, a structural analog of gamma aminobutyric acid, is used as an anticonvulsant drug since 1993. In addition, it has been effective in neuropathic pain,[<xref ref-type="bibr" rid="CIT4">4</xref>] diabetic neuropathy,[<xref ref-type="bibr" rid="CIT5">5</xref>] post-herpatic neuralgia,[<xref ref-type="bibr" rid="CIT6">6</xref>] and reflex sympathetic dystrophy.[<xref ref-type="bibr" rid="CIT7">7</xref>] Pre-treatment with gabapentin can block the development of hyperalgesia.[<xref ref-type="bibr" rid="CIT8">8</xref>] Studies have demonstrated that mechanical hyperalgesia surrounding the wound in post-operative patients and experimentally, heat-induced, secondary hyperalgesia share a common mechanism and that central neuronal sensitization contributes to post-operative pain.[<xref ref-type="bibr" rid="CIT9">9</xref>] Gabapentin has a selective effect on the nociceptive process involving central sensitization.[<xref ref-type="bibr" rid="CIT8">8</xref>] Gabapentin and morphine have synergistic analgesic effects in animals and in humans.[<xref ref-type="bibr" rid="CIT10">10</xref>&#x02013;<xref ref-type="bibr" rid="CIT12">12</xref>] The aim of this study is to know the effect of oral gabapentin given pre-operatively on post-operative pain in patients undergoing abdominal surgeries lasting for around 2 h.</p><sec id="sec2-1"><title>Aims</title><p>To study the effect of oral gabapentin 600 mg given 1 h prior to surgery as preemptive analgesia to attenuate post-operative pain in patients undergoing abdominal surgery under GA.</p></sec></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>After obtaining the approval of the Institutional Ethics Committee (Grant Medical College and Sir J J Groups of Hospitals) and written informed consent from the patients, 60 patients were included.</p><sec id="sec2-2"><title>Inclusion criteria</title><p><list list-type="order"><list-item><p>Patients belonging to American Society of Anesthesiologists physical status I and II</p></list-item><list-item><p>Patients undergoing elective surgery under general anesthesia</p></list-item><list-item><p>Anticipated duration of surgery less than 4 h</p></list-item><list-item><p>Age group between 18 and 65 years</p></list-item><list-item><p>Weight range up to 20% of the ideal body weight for either sex</p></list-item><list-item><p>Hemodynamic ally stable</p></list-item></list></p></sec><sec id="sec2-3"><title>Exclusion criteria</title><p><list list-type="order"><list-item><p>Patients with a history of hypertension, diabetes, and liver disease</p></list-item><list-item><p>Patients with acute or chronic renal disease</p></list-item><list-item><p>Patients with known neurological disease</p></list-item><list-item><p>Neurosurgical and cardiovascular surgical cases</p></list-item><list-item><p>Pregnant patients</p></list-item><list-item><p>Patients with known psychiatric disorders</p></list-item><list-item><p>Patients with anticipated difficult airway</p></list-item><list-item><p>Patients on antihypertensive drugs, sedatives, hypnotics, antidepressants, and drugs with effects on the nervous system</p></list-item><list-item><p>Patients already taking oral gabapentin</p></list-item><list-item><p>Patients allergic to opioids and Tramadol</p></list-item></list></p><p>Patients were randomly divided into two groups, with 30 patients in each group. They were randomly allocated according to computer-generated randomization. Patients in the control group received oral placebo capsules and those in the gabapentin group received 600 mg gabapentin (Neurontin 300 mg capsule; Pfizer, Mumbai, India) 1 h before surgery. The study drugs were prepared by the pharmacy and an appropriate code number was assigned.</p><p>In the operating room, a crystalloid infusion was started through an IV cannula. Blood pressure (MAP), heart rate (HR), and peripheral oxygen saturation (SpO<sub>2</sub>) were monitored. For pre-medication, midazolam 0.07 mg/kg, glycopyrolate 0.004 mg/kg, and fentanyl 2&#x000b5;g/kg were administered intravenously on the table. After adequate pre-oxygenation for 3 min, anesthesia was induced with propofol 2 mg/kg and vecuronium 0.1 mg/kg and maintained with 60% N<sub>2</sub>O in O<sub>2</sub> on Bain&#x02019;s circuit and vecuronium 0.02 mg/kg. At the end of surgery, neuromuscular block was antagonized with neostigmine 0.05 mg/kg and glycopyrolate 0.008 mg/kg. Surgeries lasting for more than 1 h were given a repeat dose of fentanyl 1&#x000b5;g/kg at the end of the first hour of induction. Any increase in the HR and MAP when not settling down by deepening the plain of anesthesia was given fentanyl 0.05 &#x000b5;g/kg subsequently. Total duration of the surgery in both the groups and the intra-operative fentanyl in both the groups were studied.</p><p>After tracheal extubation, patients were observed in the PACU for 1 h and then transferred to the surgical ward. Assessment of post-operative pain was made on the basis of the visual analog score (VAS), where 0 cm - &#x0201c;no pain&#x0201d; and 10 cm - &#x0201c;worst pain imaginable.&#x0201d; The VAS scores are taken immediately on extubation (0 h) and at 2, 4 6, 12, and 24 hours post-operatively.</p><p>Post-operative analgesia was provided with Tramadol intravenously. The first dose was given in the PACU as 2 mg/kg and repeated at 8 and 16 h. If the patient still complained of pain, then rescue analgesia was given with diclofenac 75 mg slow intravenous over 10 min. The number of doses of rescue analgesia in both the groups were studied and compared. The occurrence of any side-effects, such as nausea and vomiting, respiratory depression, dizziness, somnolence, headache, and pruritus was recorded. Tramadol dose was omitted if the patient had a respiratory rate &#x0003c;12 breaths/min, an SpO<sub>2</sub> measured by pulse oximetry &#x0003c;95%, or a serious adverse event related to opioid administration.</p></sec></sec><sec id="sec1-3"><title>RESULTS</title><p>As seen in Tables <xref ref-type="table" rid="T0001">1</xref>, <xref ref-type="table" rid="T0002">2</xref>, <xref ref-type="table" rid="T0003">2a</xref> and <xref ref-type="table" rid="T0004">3</xref>, patients in both the groups are comparable in terms of demographic parameters like age, sex ratio, and weight.</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Independent <italic>t</italic>-test for equality of mean age in two study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1"><italic>t</italic></th><th align="center" rowspan="1" colspan="1">Df</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">37.8</td><td align="center" rowspan="1" colspan="1">13.2</td><td align="center" rowspan="1" colspan="1">&#x02212;0.805</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.424</td><td align="left" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">40.4</td><td align="center" rowspan="1" colspan="1">11.8</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>Comparison of sex distribution in two study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="left" rowspan="1" colspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">Male (%)</th><th align="center" rowspan="1" colspan="1">Female (%)</th><th align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">12 (40)</td><td align="center" rowspan="1" colspan="1">18 (60)</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">12 (40)</td><td align="center" rowspan="1" colspan="1">18 (60)</td><td align="center" rowspan="1" colspan="1">30</td></tr></tbody></table></table-wrap><table-wrap id="T0003" position="float"><label>Table 2a</label><caption><p>Chi-square test for comparison of sex in the study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Pearson Chi-square</th><th align="center" rowspan="1" colspan="1">Value</th><th align="center" rowspan="1" colspan="1">df</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.000</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">Not significant</td></tr></tbody></table></table-wrap><table-wrap id="T0004" position="float"><label>Table 3</label><caption><p>Independent <italic>t</italic>-test for equality of mean weight in the two study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1"><italic>t</italic></th><th align="center" rowspan="1" colspan="1">Df</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">55.0</td><td align="center" rowspan="1" colspan="1">8.1</td><td align="center" rowspan="1" colspan="1">0.421</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.675</td><td align="left" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">54.2</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>As seen from Tables <xref ref-type="table" rid="T0005">4</xref> and <xref ref-type="table" rid="T0006">5</xref>, there is no significant difference between the groups in terms of total duration of surgery and intraoperative fentanyl usage.</p><table-wrap id="T0005" position="float"><label>Table 4</label><caption><p>Independent <italic>t</italic>-test for equality of men duration of surgery in the two groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1"><italic>t</italic></th><th align="center" rowspan="1" colspan="1">Df</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">122.0</td><td align="center" rowspan="1" colspan="1">30.1</td><td align="center" rowspan="1" colspan="1">0.645</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.521</td><td align="left" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">117.2</td><td align="center" rowspan="1" colspan="1">27.9</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="T0006" position="float"><label>Table 5</label><caption><p>Independent <italic>t</italic>-test (mean dose of inj. Fentanyl in &#x000b5;g)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1"><italic>t</italic></th><th align="center" rowspan="1" colspan="1">Df</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">146.3</td><td align="center" rowspan="1" colspan="1">32.3</td><td align="center" rowspan="1" colspan="1">&#x02212;0.258</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.798</td><td align="left" rowspan="1" colspan="1">Not significant</td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">148.3</td><td align="center" rowspan="1" colspan="1">27.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>As seen from Tables <xref ref-type="table" rid="T0007">6</xref> and <xref ref-type="table" rid="T0008">7</xref> and <xref ref-type="fig" rid="F0001">Figure 1</xref>, the VAS scores are significantly lower in the gabapentin 600 mg group as compared to placebo at 0, 2, 4, 6, 12, and 24 h of surgery.</p><fig id="F0001" position="float"><label>Figure 1</label><caption><p>Graph comparing visual analog score in two groups</p></caption><graphic xlink:href="SJA-4-137-g001"/></fig><table-wrap id="T0007" position="float"><label>Table 6</label><caption><p>Independent <italic>t</italic>-test (mean VAS)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Vas</th><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">N</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th><th align="center" rowspan="1" colspan="1">t</th><th align="center" rowspan="1" colspan="1">Df</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">VAS 0 h</td><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1">&#x02212;3.227</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">VAS 2 h</td><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">2.3</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1">&#x02212;3.928</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">3.0</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">VAS 4 h</td><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">3.2</td><td align="center" rowspan="1" colspan="1">0.8</td><td align="center" rowspan="1" colspan="1">&#x02212;2.850</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">3.7</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">VAS 6 h</td><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1">&#x02212;9.050</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">4.4</td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">VAS 12 h</td><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">3.6</td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1">&#x02212;6.530</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">VAS 24 h</td><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">3.7</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1">&#x02212;5.046</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">4.6</td><td align="center" rowspan="1" colspan="1">0.6</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>VAS: Visual analog score</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0008" position="float"><label>Table 7</label><caption><p>Comparison of the VAS between the study groups (Repeated measure ANOVA)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Vas</th><th align="center" colspan="4" rowspan="1">Gabapentin 600 mg<hr/></th><th align="center" colspan="3" rowspan="1">Control<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">Mean</th><th align="center" colspan="2" rowspan="1">SD</th><th align="center" colspan="2" rowspan="1">Mean</th><th align="center" rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">VAS 0 h</td><td align="center" colspan="2" rowspan="1">1.9</td><td align="center" colspan="2" rowspan="1">0.7</td><td align="center" colspan="2" rowspan="1">2.4</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS 2 h</td><td align="center" colspan="2" rowspan="1">2.3</td><td align="center" colspan="2" rowspan="1">0.7</td><td align="center" colspan="2" rowspan="1">3.0</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS 4 h</td><td align="center" colspan="2" rowspan="1">3.2</td><td align="center" colspan="2" rowspan="1">0.8</td><td align="center" colspan="2" rowspan="1">3.7</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS 6 h</td><td align="center" colspan="2" rowspan="1">2.9</td><td align="center" colspan="2" rowspan="1">0.7</td><td align="center" colspan="2" rowspan="1">4.4</td><td align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS 12 h</td><td align="center" colspan="2" rowspan="1">3.6</td><td align="center" colspan="2" rowspan="1">0.6</td><td align="center" colspan="2" rowspan="1">4.6</td><td align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">VAS 24 h</td><td align="center" colspan="2" rowspan="1">3.7</td><td align="center" colspan="2" rowspan="1">0.7</td><td align="center" colspan="2" rowspan="1">4.6</td><td align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" colspan="8" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Group</bold></td><td align="left" rowspan="1" colspan="1"><bold>Treatment</bold></td><td align="center" rowspan="1" colspan="1"><bold>N</bold></td><td align="center" rowspan="1" colspan="1"><bold>Sum of squares</bold></td><td align="center" rowspan="1" colspan="1"><bold>df</bold></td><td align="center" rowspan="1" colspan="1"><bold>F</bold></td><td align="center" rowspan="1" colspan="1"><bold><italic>P</italic>-value</bold></td><td align="left" rowspan="1" colspan="1"><bold>Significance</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">66.74</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">113.2</td><td align="center" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1">Significant</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>VAS: Visual analog score</p></fn></table-wrap-foot></table-wrap><p>As seen from Table <xref ref-type="table" rid="T0009">8</xref>, <xref ref-type="table" rid="T0010">8a</xref> and <xref ref-type="fig" rid="F0002">Figure 2</xref>, three patients in the gabapentin group required rescue analgesia in terms of diclofenac intravenously as compared to 13 patients in the placebo group. The three patients in the gabapentin group requiring rescue analgesia were at around 4, 7, and 12 h after surgery, respectively. Of the 13 patients requiring rescue analgesia, only one patient required it twice, at 4 and 16 h post-surgery, respectively. But, as seen, the rescue analgesia requirement in the gabapentin group was significantly lower as compared to the placebo group.</p><fig id="F0002" position="float"><label>Figure 2</label><caption><p>Rescue analgesia requirement in both groups in post-operative period</p></caption><graphic xlink:href="SJA-4-137-g002"/></fig><table-wrap id="T0009" position="float"><label>Table 8</label><caption><p>Rescue analgesia requirement in two study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="left" rowspan="1" colspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">No (%)</th><th align="center" rowspan="1" colspan="1">Yes (%)</th><th align="center" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Gabapentin 600 mg</td><td align="center" rowspan="1" colspan="1">27 (90.00)</td><td align="center" rowspan="1" colspan="1">3 (10.00)</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Control</td><td align="center" rowspan="1" colspan="1">17 (56.67)</td><td align="center" rowspan="1" colspan="1">13 (43.33)</td><td align="center" rowspan="1" colspan="1">30</td></tr></tbody></table><table-wrap-foot><fn><p>Figures in parentheses are in percentage</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0010" position="float"><label>Table 8a</label><caption><p>Chi-square test for comparison of rescue analgesia in the study groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Pearson chi-square</th><th align="center" rowspan="1" colspan="1">Value</th><th align="center" rowspan="1" colspan="1">df</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" rowspan="1" colspan="1">Significance</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8.523</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">Significant</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>The results of our pre-operative oral single-dose study investigating the acute post-operative analgesic effects of gabapentin in patients undergoing abdominal surgeries requiring general anesthesia show that gabapentin decreased post-operative pain scores at 0, 2, 4, 6, 12, and 24 h of surgery and decreased requirement of rescue analgesia when compared with placebo.</p><p>Post-operative pain is not purely nociceptive in nature and may consist of inflammatory, neurogenic, and visceral components. Therefore, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are becoming increasingly popular.[<xref ref-type="bibr" rid="CIT1">1</xref>] The main aim in combining different analgesic drugs is to obtain synergistic or additive analgesia, allowing a smaller dose of each drug with an improved safety profile. This can be achieved by combining analgesics acting at different locations (<italic>e.g</italic>., centrally and peripherally acting analgesics). We used Tramadol as a fixed-dose regimen for postoperative pain control and Diclofenac as rescue analgesia to be given only when the patient demanded for it. Tramadol is widely used for moderate-to-severe post-operative pain. Its efficacy is a result of two complementary mechanisms of action: stimulation of &#x000b5;-opioid receptors and inhibition of norepinephrine and 5-hydroxytryptamine reuptake in pain pathways.[<xref ref-type="bibr" rid="CIT13">13</xref>]</p><p>Non-steroidal anti-inflammatory drugs are commonly used analgesics for minor surgery and are useful adjunctive analgesics in patients undergoing major surgery, decreasing pain and opioid requirements. They are well established, effective, and inexpensive. However, their use may be limited by adverse renal, gastrointestinal, and hemostatic effects.</p><p>Antihyperalgesic drugs such as gabapentin may have a role in post-operative pain, and the combination with other antinociceptive drugs may produce synergistic analgesia effects.[<xref ref-type="bibr" rid="CIT9">9</xref><xref ref-type="bibr" rid="CIT10">10</xref>]</p><p>Significantly low VAS scores immediately after extubation, i.e. 0 h (1.9 <italic>vs</italic>. 2.4, <italic>P</italic>=0.002) in the gabapentin group may suggest the synergistic effect of gabapentin with fentanyl. Decreased rescue analgesic requirement in the gabapentin group also suggests the synergistic effect of gabapentin with Tramadol.</p><p>Turan <italic>et al</italic>, in 2004, also found that 1,200 mg gabapentin given 1 h prior to surgery significantly reduced the post-operative pain scores and Tramadol requirements in Total abdominal hysterectomy patients.</p><p>In animal models of nociception, gabapentin reduces the hypersensitivity associated with nerve injury, inflammation, and pain after surgery.[<xref ref-type="bibr" rid="CIT8">8</xref><xref ref-type="bibr" rid="CIT9">9</xref>] Mechanical hyperalgesia surrounding the wound in post-operative patients and experimental, heat-induced secondary hyperalgesia share a common mechanism -central neuronal sensitization, which may contribute to some aspects of post-operative pain. Antihyperalgesic drugs such as gabapentin may have a role in post-operative pain, and the combination with other antinociceptive drugs may produce synergistic analgesia effects.[<xref ref-type="bibr" rid="CIT9">9</xref><xref ref-type="bibr" rid="CIT10">10</xref>] Gabapentin enhanced the analgesic effect of morphine in healthy volunteers,[<xref ref-type="bibr" rid="CIT11">11</xref>] and the combination produced better analgesia in comparison with morphine alone in patients suffering neuropathic cancer pain.[<xref ref-type="bibr" rid="CIT12">12</xref>]</p><p>Gabapentin significantly decreased morphine consumption and pain in patients after mastectomy[<xref ref-type="bibr" rid="CIT13">13</xref>] although the patients were evaluated for only 4 h after surgery.</p><p>Gabapentin is well tolerated. It has few side-effects and minor interactions with other drugs when used for the treatment of chronic pain.[<xref ref-type="bibr" rid="CIT7">7</xref>] We did not observe any significant side-effects associated with a single oral dose of gabapentin. Our results are similar to other published reports.[<xref ref-type="bibr" rid="CIT14">14</xref>&#x02013;<xref ref-type="bibr" rid="CIT17">17</xref>]</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>Preemptive use of gabapentin significantly decreases the post-operative pain and rescue analgesic requirement in patients undergoing abdominal surgery under general anesthesia.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="CIT1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>BM</given-names></name><name><surname>Liu</surname><given-names>SS</given-names></name><name><surname>Rowlingson</surname><given-names>AJ</given-names></name><name><surname>Cowan</surname><given-names>AR</given-names></name><name><surname>Cowan</surname><given-names>JA</given-names></name><name><surname>Block</surname><given-names>CL</given-names></name></person-group><article-title>Efficacy of postoperative epidural analgesia: A metaanalysis</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>2455</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">14612482</pub-id></element-citation></ref><ref id="CIT2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickenson</surname><given-names>A</given-names></name></person-group><article-title>Neurophysiology of opioid poorly responsive pain</article-title><source>Cancer Surv</source><year>1994</year><volume>21</volume><fpage>5</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">8564999</pub-id></element-citation></ref><ref id="CIT3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fishman</surname><given-names>S</given-names></name><name><surname>Borsook</surname><given-names>D</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Benzon</surname><given-names>H</given-names></name><name><surname>Raja</surname><given-names>S</given-names></name><name><surname>Molloy</surname><given-names>RE</given-names></name><name><surname>Strichartz</surname><given-names>G</given-names></name></person-group><article-title>Opioids in pain management</article-title><source>Essentials of pain medicine and regional anesthesia</source><year>1999</year><publisher-loc>New York</publisher-loc><publisher-name>Churchill Livingstone</publisher-name><fpage>51</fpage><lpage>4</lpage></element-citation></ref><ref id="CIT4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosner</surname><given-names>H</given-names></name><name><surname>Rubin</surname><given-names>L</given-names></name><name><surname>Kestenbaum</surname><given-names>A</given-names></name></person-group><article-title>Gabapentin adjunctive therapy in neuropathic pain states</article-title><source>Clin J Pain</source><year>1996</year><volume>12</volume><fpage>56</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8722736</pub-id></element-citation></ref><ref id="CIT5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backonja</surname><given-names>M</given-names></name><name><surname>Beydoun</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>KR</given-names></name><name><surname>Schwartz</surname><given-names>SL</given-names></name><name><surname>Fonseca</surname><given-names>V</given-names></name><name><surname>Hes</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial</article-title><source>JAMA</source><year>1998</year><volume>280</volume><fpage>1831</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9846777</pub-id></element-citation></ref><ref id="CIT6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowbotham</surname><given-names>M</given-names></name><name><surname>Harden</surname><given-names>N</given-names></name><name><surname>Stacey</surname><given-names>B</given-names></name><name><surname>Bernstein</surname><given-names>P</given-names></name><name><surname>Magnus-Miller</surname><given-names>L</given-names></name></person-group><article-title>Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial</article-title><source>JAMA</source><year>1998</year><volume>280</volume><fpage>1837</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">9846778</pub-id></element-citation></ref><ref id="CIT7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellick</surname><given-names>GA</given-names></name><name><surname>Mellick</surname><given-names>LB</given-names></name></person-group><article-title>Reflex sympathetic dystrophy treated with gabapentin</article-title><source>Arch Phys Med Rehabil</source><year>1997</year><volume>78</volume><fpage>98</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">9014968</pub-id></element-citation></ref><ref id="CIT8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name></person-group><article-title>gabapentin in pain management</article-title><source>Anesth Analg</source><year>2000</year><volume>91</volume><fpage>680</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10960399</pub-id></element-citation></ref><ref id="CIT9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirks</surname><given-names>J</given-names></name><name><surname>Moiniche</surname><given-names>S</given-names></name><name><surname>Hilsted</surname><given-names>KL</given-names></name><name><surname>Dahl</surname><given-names>JB</given-names></name></person-group><article-title>Mechanisms of postoperative pain: Clinical indications for a contribution of central neuronal sensitization</article-title><source>Anesthesiology</source><year>2002</year><volume>97</volume><fpage>1591</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12459689</pub-id></element-citation></ref><ref id="CIT10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimoyama</surname><given-names>M</given-names></name><name><surname>Shimoyama</surname><given-names>N</given-names></name><name><surname>Inturrisi</surname><given-names>CE</given-names></name><name><surname>Elliott</surname><given-names>KJ</given-names></name></person-group><article-title>gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test</article-title><source>Pain</source><year>1997</year><volume>72</volume><fpage>375</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">9313278</pub-id></element-citation></ref><ref id="CIT11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckhardt</surname><given-names>K</given-names></name><name><surname>Ammon</surname><given-names>S</given-names></name><name><surname>Hofmann</surname><given-names>U</given-names></name><name><surname>Riebe</surname><given-names>A</given-names></name><name><surname>Gugeler</surname><given-names>N</given-names></name><name><surname>Mikus</surname><given-names>G</given-names></name></person-group><article-title>Gabapentin enhances the analgesic effect of morphine in healthy volunteers</article-title><source>Anesth Analg</source><year>2000</year><volume>91</volume><fpage>185</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">10866910</pub-id></element-citation></ref><ref id="CIT12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caraceni</surname><given-names>A</given-names></name><name><surname>Zecca</surname><given-names>E</given-names></name><name><surname>Martini</surname><given-names>C</given-names></name><name><surname>De Conno</surname><given-names>F</given-names></name></person-group><article-title>Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain</article-title><source>J Pain Symptom Manage</source><year>1999</year><volume>17</volume><fpage>441</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">10388250</pub-id></element-citation></ref><ref id="CIT13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirks</surname><given-names>J</given-names></name><name><surname>Fredensborg</surname><given-names>BB</given-names></name><name><surname>Christensen</surname><given-names>D</given-names></name><name><surname>Fomsgaard</surname><given-names>JS</given-names></name><name><surname>Flyger</surname><given-names>H</given-names></name><name><surname>Dahl</surname><given-names>JB</given-names></name></person-group><article-title>A randomized study of the effects of single dose gabapentin versus placebo on postoperative pain and morphine consumption after mastectomy</article-title><source>Anesthesiology</source><year>2002</year><volume>97</volume><fpage>560</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12218520</pub-id></element-citation></ref><ref id="CIT14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>CK</given-names></name><name><surname>Priye</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>U</given-names></name><name><surname>Singh</surname><given-names>RB</given-names></name><name><surname>Singh</surname><given-names>PK</given-names></name></person-group><article-title>Preemptive use of gabapentin significantly decreases postoperative pain and rescue analgesic requirement in laparoscopic cholecystectomy</article-title><source>Can J Anaesth</source><year>2004</year><volume>51</volume><fpage>358</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15064265</pub-id></element-citation></ref><ref id="CIT15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turan</surname><given-names>A</given-names></name><name><surname>Karamanlio&#x0011f;lu</surname><given-names>B</given-names></name><name><surname>Memi&#x0015f;</surname><given-names>D</given-names></name><name><surname>Usar</surname><given-names>P</given-names></name><name><surname>Pamuk&#x000e7;u</surname><given-names>Z</given-names></name><name><surname>T&#x000fc;re</surname><given-names>M</given-names></name></person-group><article-title>The analgesic effects of gabapentin after total abdominal hysterectomy</article-title><source>Anesth Analg</source><year>2004</year><volume>98</volume><fpage>1370</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">15105217</pub-id></element-citation></ref><ref id="CIT16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rorarius</surname><given-names>MG</given-names></name><name><surname>Mennander</surname><given-names>S</given-names></name><name><surname>Suominen</surname><given-names>P</given-names></name><name><surname>Rintala</surname><given-names>S</given-names></name><name><surname>Puura</surname><given-names>A</given-names></name><name><surname>Pirhonen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Gabapentin for the prevention of postoperative pain after vaginal hysterectomy</article-title><source>Pain</source><year>2004</year><volume>110</volume><fpage>175</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">15275765</pub-id></element-citation></ref><ref id="CIT17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>CK</given-names></name><name><surname>Singhal</surname><given-names>V</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name><name><surname>Lakra</surname><given-names>A</given-names></name><name><surname>Ranjan</surname><given-names>R</given-names></name><name><surname>Pal</surname><given-names>R</given-names></name><etal/></person-group><article-title>Gabapentin provides effective postoperative analgesia whether administered preemptively or post-incision</article-title><source>Can J Anaesth</source><year>2005</year><volume>52</volume><fpage>827</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">16189334</pub-id></element-citation></ref></ref-list></back></article>